Matthew J. D'Onofrio, San Diego, CA (US); David A. Gonyer, Cardiff, CA (US); Shirish A. Shah, Phoenix, AZ (US); and Stuart J. Madden, Ellicott City, MD (US)
Assigned to Evoke Pharma, Inc., Solana Beach, CA (US)
Filed by Evoke Pharma, Inc., Solana Beach, CA (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,829.
Application 17/366,829 is a continuation of application No. 17/100,664, filed on Nov. 20, 2020, granted, now 11,628,150.
Application 17/100,664 is a continuation of application No. 16/181,841, filed on Nov. 6, 2018, granted, now 11,020,361, issued on Jun. 1, 2021.
Application 16/181,841 is a continuation of application No. 15/130,086, filed on Apr. 15, 2016, abandoned.
Application 15/130,086 is a continuation of application No. 13/660,709, filed on Oct. 25, 2012, abandoned.
Application 13/660,709 is a continuation of application No. 12/645,108, filed on Dec. 22, 2009, granted, now 8,334,281, issued on Dec. 18, 2012.
Claims priority of provisional application 61/140,034, filed on Dec. 22, 2008.
Prior Publication US 2021/0338608 A1, Nov. 4, 2021
1. An intranasal pharmaceutical composition having a pH of above about 4.5, comprising metoclopramide, or a pharmaceutically acceptable salt thereof, and either (1) benzalkonium chloride at a concentration of at least 0.025% (w/v) and up to about 0.05% (w/v) or (2) benzyl alcohol at a concentration of less than 1% (w/v); wherein the intranasal pharmaceutical composition exhibits less than about 2% average change in percent optical density (O.D.) per week per 200 mg/mL of metoclopramide when stored at a temperature of 40° C. and 75% relative humidity for at least about 4 weeks.